BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 38485644)

  • 1. Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing.
    Zara Rozalen A; Martin JM; Rajendran R; Jain M; Nava VE
    Curr Oncol; 2024 Mar; 31(3):1556-1561. PubMed ID: 38534951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
    Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology: Rare Biopsy Cases Lacking Associated Invasive High-grade Carcinoma.
    Russell DH; Epstein JI
    Am J Surg Pathol; 2022 Feb; 46(2):233-240. PubMed ID: 34619708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
    Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
    BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma.
    Shah RB; Yoon J; Liu G; Tian W
    Histopathology; 2017 Nov; 71(5):693-702. PubMed ID: 28570007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
    Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
    Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.
    Shah RB; Zhou M
    Adv Anat Pathol; 2012 Jul; 19(4):270-8. PubMed ID: 22692290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Understanding and Management of Intraductal Carcinoma of the Prostate.
    Considine B; Adeniran A; Hurwitz ME
    Curr Oncol Rep; 2021 Jul; 23(9):110. PubMed ID: 34272624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
    Kang M; Lee H; Byeon SJ; Kwon GY; Jeon SS
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular complexity of intraductal carcinoma of the prostate.
    Zhu S; Xu N; Zeng H
    Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cribriform Lesions of the Prostate Gland.
    Cai Q; Shah RB
    Surg Pathol Clin; 2022 Dec; 15(4):591-608. PubMed ID: 36344177
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.